A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the reasonable dosage of SHR-A2102 for Advanced Solid Tumors.
Advanced Solid Tumors
DRUG: SHR-A2102|DRUG: SHR-A2102 ; Adebrelimab injection
RP2D, through phase IB completion, an average of 1 years|Incidence and severity of AEï¼›, from Day1 to 90 days after last dose|ORR, 18 months after the last subject was enrolled in the group
DCR(Investigator evaluation), 18 months after the last subject was enrolled in the group|DoR(Investigator evaluation), 18 months after the last subject was enrolled in the group|PFS(Investigator evaluation), 18 months after the last subject was enrolled in the group|OS(Investigator evaluation), 18 months after the last subject was enrolled in the group|SHR-A2102 and free toxin PK, through study completion, an average of 2 years|SHR-1316 PK, through study completion, an average of 2 years|SHR-A2102 Immunogenicity, through study completion, an average of 2 years|SHR 1316 Immunogenicity, through study completion, an average of 2 years
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the reasonable dosage of SHR-A2102 for Advanced Solid Tumors.